Neuromedical Systems Papnet identifies 97.1% of lung cancer-positive sputum samples -- study.
This article was originally published in The Gray Sheet
NEUROMEDICAL SYSTEMS PAPNET IDENTIFIES 97.1% OF POSITIVE LUNG CANCER SAMPLES in prescreened positive sputum samples, a study by Leopold Koss, MD, Montefiore Medical Center-Albert Einstein College of Medicine, New York, et al. concludes. The study was published in the July issue of Human Pathology.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.